Waldenström macroglobulinemia, EU positive opinion for a new drug

New treatment perspectives open up for adult patients with Waldenström’s macroglobulinemia, a rare lymphoma that accounts for approximately 1% of all non-Hodgkin’s lymphomas. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (Ema) adopted a positive opinion recommending the approval of zanubrutinib for the treatment of adult patients with Waldenström macroglobulinemia who have previously received at least one first-line therapy and for patients unsuitable for chemo-immunotherapy.